Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.

(Reuters) - Zoetis raised its annual profit and revenue forecasts on Monday on strong ... Rival Merck also reported 17% sales growth in its companion animal health business in the third quarter ...

Animal health and vaccine products are core growth drivers. Merck boasts a strong cancer pipeline, including Keytruda. However, generic competition for several drugs and rising competitive ...

Merck has acquired Modifi ... has approved Elanco Animal Health's oral drug to protect dogs against six parasitic infections, the company said on Monday. Johnson & Johnson said on Monday it ...

Merck Animal Health, a division of Merck & Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the industry’s first monitoring technology for dairy calves from birth ...

Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda. Merck is investing in M&A activity to strengthen its pipeline.

You've got Zoetis in green, Merck in yellow, and Johnson & Johnson in red. Again, impressive for Zoetis. Out of animal health, you're generating the highest return on assets and the steadiest.

other industries], biomaterials & green chemicals), food, animal health & agricultural applications (flavours ... synthetic biology market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), ...